Response to: 'JAK inhibitors as promising agents for refractory Takayasu arteritis' by Watanabe.

Volume: 81, Issue: 4, Pages: e68 - e68
Published: Apr 1, 2022
Abstract
We thank Watanabe for his interest in our case report showing that tofacitinib, a janus kinase (JAK) inhibitor, successfully induced a remission of Takayasu arteritis (TAK) complicated by ulcerative colitis (UC)1 and for providing some meaningful comments to supplement our discussion.2 Watanabe wonders if JAK inhibitors can be effective in TAK patients without UC. In addition, he is concerned that types of JAK inhibitors may affect the...
Paper Details
Title
Response to: 'JAK inhibitors as promising agents for refractory Takayasu arteritis' by Watanabe.
Published Date
Apr 1, 2022
Volume
81
Issue
4
Pages
e68 - e68
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.